Full Press Release Details
Bio Solutions Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission
Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection
510(k) Clearance Would Enable the Introduction of INBS' Technology to the US in 2025
YORK, November 13, 2024 - Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"),
a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced strong initial results from
its Pharmacokinetic (PK) study required for an FDA 510(k) submission. The data from the PK study shows that fingerprint sweat mimics
the rate and extent of codeine in blood and saliva. The study successfully demonstrated that fingerprint sweat provides a reliable sample
matrix for drug detection, showing quantitative PK data closely aligned to blood, based on statistical comparisons made at the 95% confidence
close correlation of PK parameters in fingerprint sweat and blood highlights its robustness as a sampling approach. While independent
data has consistently supported this, our clinical study further reinforces these findings," said Harry Simeonidis, President and
CEO of Intelligent Bio Solutions. "We are very pleased with the PK study results. This data highlights the potential for our technology
to achieve widespread adoption in safety-critical industries and beyond, marking a significant achievement as we advance toward FDA clearance
in the United States."
510(k) clearance would enable INBS to introduce its innovative drug screening technology to the US market in 2025. The PK study results
and other clinical data from the Company's clinical study plan will be submitted as part of the Company's 510(k) submission,
expected in the fourth calendar quarter of this year. INBS is well-positioned to meet the increasing demand for drug testing in the United
States, particularly in safety-critical industries like construction, mining, and transportation, as well as in law enforcement, drug
rehabilitation, and forensic sectors.
Average Codeine Values in Whole Blood, Oral Fluid and Fingerprint Sweat1
results are not included in this chart. Due to the nature of urine sample collection, which depends on an individual's need to
urinate, samples cannot be collected at fixed intervals. Therefore, urine specimens were collected on an ad-lib basis as frequently
study results show that fingerprint sweat is a strong indicator of codeine ingestion. They further validate the ability of INBS'
method to provide rapid and reliable drug screening through a simple fingerprint sweat sample without invasive procedures.
PK study, conducted in partnership with Cliantha Research, required a minimum of 36 subjects. The Company successfully recruited 39 healthy
adult subjects from diverse backgrounds, including varying genders, ages, and ethnicities. The study compared the levels of opiates detected
in fingerprint sweat with those found in blood, oral fluid, and urine samples following the medically supervised administration of codeine.
All fingerprint sweat specimens collected using INBS' Intelligent Fingerprinting Drug Screening System, were analyzed by a
validated, traceable liquid chromatography/tandem mass spectrometry (LC-MS/MS) method, widely accepted as the gold standard for
Intelligent Bio Solutions
Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company
believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis,
which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens
for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection
in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The
Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics
firms, drug treatment organizations, and coroners.
more information, visit: http://www.ibs.inc/
of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties.
Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully
develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure
regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or
implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology,
including "believes," "estimates," "anticipates," "expects," "plans," "projects,"
"intends," "potential," "may," "could," "might," "will," "should,"
"approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent
Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this
release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained
in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Pinto, Managing Director
Strategic Communications